解脲脲支原体耐药性分析及生物分群研究  

Study on antimicrobial resistance and biovar of Ureaplasma urealyticum

作　　者：王鹏[1] 王群兴[1] 向希映[1] 陈春燕[1] 

机构地区：[1]三峡大学第一临床医学院宜昌市中心人民医院检验科,湖北宜昌443003

出　　处：《中华医院感染学杂志》2013年第20期4871-4873,共3页Chinese Journal of Nosocomiology

摘　　要：目的了解女性泌尿生殖道解脲脲支原体的耐药性及生物分群状况,为临床合理使用抗菌药物提供依据。方法采用法国生物梅里埃公司支原体培养、鉴定、计数及药敏试验试剂盒,对334株解脲脲支原体进行药敏试验;采用PCR基因扩增方法对其中60株解脲脲支原体临床分离株进行生物分群研究。结果 334株解脲脲支原体对普那霉素、多西环素、四环素的耐药率较低,分别为1.20%、8.98%、7.49%,耐药率较高有环丙沙星、氧氟沙星,分别为83.83%、56.29%;60株解脲脲支原体临床分离株中Parvo生物群41株占68.33%,T960生物群19株占31.67%。结论多西环素、交沙霉素和克拉霉素可作为解脲脲支原体临床治疗感染的首选药物,应根据药敏试验结果合理选用抗菌药物延缓耐药株的产生,门诊女性患者解脲脲支原体以Parvo生物群为主。OBJECTIVE To investigate the antimicrobial resistance and distribution of biovar of clinical isolates of Ureaplasma urealyticurn （Uu） from urogenitory tracts of women so as to provide guidance for reasonable clinical use of antibiotics. METHODS By means of drug susceptibility testing kit of BioMerieux, France for the culture, identification, and counting of Mycoplasma, the drug susceptibility testing was performed for Uu cultured positive from 334 specimens, then the PCR gene amplification method was employed to identify the biotypes of 60 clinical isolates of Uu. RESULTS The drug resistance rates of the 334 clinical isolates of Uu to pristinamycin, doxycycline, and tetracycline were 1. 20%, 8. 98%,and 7.49%, respectively; the drug resistance rates to ciprofloxacin and ofloxacin were 83.83% and 56.29%, respectively. Of totally 60 clinical isolates of Uu, there were 41 （68. 33%） strains of biovar Parvo and 19 （al. 67%） strains of biovar T960. CONCLUSION Doxycycline, j osamyein, and clarythromycin can be used as the preferred antibiotics for the clinical treatment of Uu infections, and the antibiotics should be used reasonably based on the result of drug susceptibility testing to delay the emergence of drug resistant strains. The Parvo is the predominant biovar of Uu from female patients of the outpatient department.

关 键 词：解脲脲支原体 耐药性 生物群 

分 类 号：R375[医药卫生—病原生物学]